These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 33662353)
1. Inhibition of matrix metalloproteinase-9 for the treatment of dry eye syndrome; a review study. Shoari A; Kanavi MR; Rasaee MJ Exp Eye Res; 2021 Apr; 205():108523. PubMed ID: 33662353 [TBL] [Abstract][Full Text] [Related]
2. In Vivo Effect of RSH-12, a Novel Selective MMP-9 Inhibitor Peptide, in the Treatment of Experimentally Induced Dry Eye Model. Shoari A; Rasaee MJ; Rezaei Kanavi M; Afsar Aski S; Tooyserkani R Curr Eye Res; 2021 Jan; 46(1):7-13. PubMed ID: 32567381 [TBL] [Abstract][Full Text] [Related]
3. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. Messmer EM; von Lindenfels V; Garbe A; Kampik A Ophthalmology; 2016 Nov; 123(11):2300-2308. PubMed ID: 27665213 [TBL] [Abstract][Full Text] [Related]
4. A highly soluble matrix metalloproteinase-9 inhibitor for potential treatment of dry eye syndrome. Mori M; De Lorenzo E; Torre E; Fragai M; Nativi C; Luchinat C; Arcangeli A Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):289-95. PubMed ID: 22520332 [TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Pflugfelder SC; Farley W; Luo L; Chen LZ; de Paiva CS; Olmos LC; Li DQ; Fini ME Am J Pathol; 2005 Jan; 166(1):61-71. PubMed ID: 15632000 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic Effects of STAT3 Inhibition on Experimental Murine Dry Eye. Qu M; Qi X; Wang Q; Wan L; Li J; Li W; Li Y; Zhou Q Invest Ophthalmol Vis Sci; 2019 Sep; 60(12):3776-3785. PubMed ID: 31503282 [TBL] [Abstract][Full Text] [Related]
7. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. Nagelhout TJ; Gamache DA; Roberts L; Brady MT; Yanni JM J Ocul Pharmacol Ther; 2005 Apr; 21(2):139-48. PubMed ID: 15857280 [TBL] [Abstract][Full Text] [Related]
8. The therapeutic effect of DA-6034 on ocular inflammation via suppression of MMP-9 and inflammatory cytokines and activation of the MAPK signaling pathway in an experimental dry eye model. Seo MJ; Kim JM; Lee MJ; Sohn YS; Kang KK; Yoo M Curr Eye Res; 2010 Feb; 35(2):165-75. PubMed ID: 20136427 [TBL] [Abstract][Full Text] [Related]
9. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Chotikavanich S; de Paiva CS; Li de Q; Chen JJ; Bian F; Farley WJ; Pflugfelder SC Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3203-9. PubMed ID: 19255163 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic Potential of the Molecular Chaperone and Matrix Metalloproteinase Inhibitor Clusterin for Dry Eye. Fini ME; Jeong S; Wilson MR Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374364 [TBL] [Abstract][Full Text] [Related]
11. [A new approach for better comprehension of diseases of the ocular surface]. Baudouin C J Fr Ophtalmol; 2007 Mar; 30(3):239-46. PubMed ID: 17417148 [TBL] [Abstract][Full Text] [Related]
12. Association of tear matrix metalloproteinase 9 immunoassay with signs and symptoms of dry eye disease: A cross-sectional study using qualitative, semiquantitative, and quantitative strategies. Lee YH; Bang SP; Shim KY; Son MJ; Kim H; Jun JH PLoS One; 2021; 16(10):e0258203. PubMed ID: 34662364 [TBL] [Abstract][Full Text] [Related]
13. Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non-Dry Eye Patients. Schargus M; Ivanova S; Kakkassery V; Dick HB; Joachim S Cornea; 2015 Jul; 34(7):739-44. PubMed ID: 25909238 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic Effect of MK2 Inhibitor on Experimental Murine Dry Eye. Wu Y; Bu J; Yang Y; Lin X; Cai X; Huang C; Zheng X; Ouyang W; Li W; Zhang X; Liu Z Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4898-4907. PubMed ID: 28973340 [TBL] [Abstract][Full Text] [Related]
15. Effects of Quercetin in a Mouse Model of Experimental Dry Eye. Oh HN; Kim CE; Lee JH; Yang JW Cornea; 2015 Sep; 34(9):1130-6. PubMed ID: 26203745 [TBL] [Abstract][Full Text] [Related]
16. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Luo L; Li DQ; Doshi A; Farley W; Corrales RM; Pflugfelder SC Invest Ophthalmol Vis Sci; 2004 Dec; 45(12):4293-301. PubMed ID: 15557435 [TBL] [Abstract][Full Text] [Related]
17. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. De Paiva CS; Corrales RM; Villarreal AL; Farley WJ; Li DQ; Stern ME; Pflugfelder SC Exp Eye Res; 2006 Sep; 83(3):526-35. PubMed ID: 16643899 [TBL] [Abstract][Full Text] [Related]
18. EMMPRIN modulates epithelial barrier function through a MMP-mediated occludin cleavage: implications in dry eye disease. Huet E; Vallée B; Delbé J; Mourah S; Prulière-Escabasse V; Tremouilleres M; Kadomatsu K; Doan S; Baudouin C; Menashi S; Gabison EE Am J Pathol; 2011 Sep; 179(3):1278-86. PubMed ID: 21777561 [TBL] [Abstract][Full Text] [Related]
19. 0.005% Preservative-Free Latanoprost Induces Dry Eye-Like Ocular Surface Damage via Promotion of Inflammation in Mice. Yang Y; Huang C; Lin X; Wu Y; Ouyang W; Tang L; Ye S; Wang Y; Li W; Zhang X; Liu Z Invest Ophthalmol Vis Sci; 2018 Jul; 59(8):3375-3384. PubMed ID: 30025085 [TBL] [Abstract][Full Text] [Related]
20. Topical Delivery of Levocarnitine to the Cornea and Anterior Eye by Thermosensitive in-situ Gel for Dry Eye Disease. Ma B; Pang L; Huang P; Bai J; Zhang Z; Wu H; Cai M; Yang J; Xu Y; Yin X; Qu C; Ni J Drug Des Devel Ther; 2021; 15():2357-2373. PubMed ID: 34121838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]